bmiMD Review

Our assessment

bmiMD does two things most of this field won't: it publishes a readable pricing ladder, and it names the legal entity behind the brand. The cheapest rung on that ladder costs you a twelve-month prepayment. A non-refundable fee applies if you cancel after your intake is approved. And the pharmacy that compounds what you inject is never named.

The ladder, and what each rung costs you

bmiMD sells compounded semaglutide and compounded tirzepatide on a ladder keyed to plan length. Each longer prepaid term buys a lower monthly rate than the one below it. Within any term you pick, the rate doesn't move as your dose goes up. There is a newer lower-dose product line priced the same way.

Plenty of providers discount for commitment. What makes bmiMD worth reading is that it publishes the rungs, so you can do the arithmetic before you hand over a card instead of meeting the structure at checkout after an intake. The usual pattern in this category is one starting-at figure with the conditions buried.

A ladder is also built to make the longest term look like the obvious choice, and it usually does — right up to month four, when something changes. Read the rungs for what they are: a discount for taking on risk the provider would otherwise carry.

The commitment, and the fee for leaving

The current tirzepatide page confirms that its lowest monthly equivalent belongs to a twelve-month plan. Selecting that tab displays a full-year total, while the one-month option costs more per month. The lowest figure is not a month-to-month offer.

There is a second condition that matters more than its size suggests. A non-refundable fee applies if you cancel after your intake has been approved. It is disclosed, and it is not large next to the cost of treatment. It is also the kind of term that feels trivial when you sign up and irritating when you leave. Paired with a prepaid year, it makes bmiMD a provider to choose deliberately rather than to try out.

The counterweight is real. bmiMD says the charge taken at checkout is only an authorization hold, and that nothing is collected if a provider turns you down. That answers the most common complaint in this category: being charged before anyone has confirmed you can have the medication.

Who is behind the brand

bmiMD says it is operated by Medccm Inc. That sounds small and isn't. A meaningful share of telehealth GLP-1 brands are marketing names attached to an entity you cannot identify. That leaves you unable to look up who you are dealing with, what else they run, or where a complaint goes once customer service stops helping. bmiMD tells you. Several providers in this comparison don't.

bmiMD also keeps a public review profile on Trustpilot rather than relying only on testimonials it selects and hosts itself. Don't read that as a quality score. A public review profile is a place to read complaints, not a rating worth trusting — but an outside venue where unhappy customers can be read is worth more than a page of curated quotes.

The gap: the pharmacy is never named

bmiMD never identifies the pharmacy that compounds and dispenses what you inject. On a compounded medication, that is the one disclosure you would most want. Set against everything else bmiMD publishes, the omission stands out rather than fading. A company that names its operating entity and prints its price ladder has decided where its openness stops.

Everything bmiMD sells in this category is compounded. Compounded semaglutide and tirzepatide are prepared by a compounding pharmacy and are not FDA-approved finished drug products. bmiMD publishes no brand-name option. That difference is the substance of the price gap between this route and a brand-name one, and it shouldn't be flattened into a comparison of two numbers.